September 2025
1. WANG L, Zang Y, Dejenie R, Bing J, et al
   The role of cytokines in ovarian cancer drug resistance.
   Int J Cancer. 2025 Sep 19. doi: 10.1002/ijc.70099.
   

   >> Share

   
   
2. ULLAH A, Chen Y, Shen Y, Shen B, et al
   Chemotherapy as a double-edged sword: Modulation of tumor-associated cytokine and chemokine responses in ovarian cancer.
   Int J Cancer. 2025 Sep 15. doi: 10.1002/ijc.70132.
   

   >> Share

   
   
3. KASPER E, Boulouard F, Basset N, Golmard L, et al
   Deciphering dual clinical entities associated with TP53 pathogenic variants: Insights from 53,085 HBOC panel analyses in French laboratories.
   Int J Cancer. 2025;157:897-907.
   

   >> Share

   
   August 2025
4. DAUGS K, Brandes D, Yasin L, Anwar A, et al
   Germline variants observed in pediatric cancer patients related to hereditary breast and ovarian cancer in adults.
   Int J Cancer. 2025 Aug 26. doi: 10.1002/ijc.70097.
   

   >> Share

   
   
5. LI H, Feng Y, Wang Z, Li X, et al
   Advances in the management of ovarian cancer liver metastasis.
   Int J Cancer. 2025 Aug 16. doi: 10.1002/ijc.70065.
   

   >> Share

   
   May 2025
6. GAMA Q, Wang L, Wu P, Liu S, et al
   Effects of levonorgestrel-releasing intrauterine system on recurrence and fertility outcomes during assisted reproduction after complete remission of early endometrioid endometrial cancer and precancerous lesions: A retrospective cohort study.
   Int J Cancer. 2025 May 14. doi: 10.1002/ijc.35465.
   

   >> Share

   
   April 2025
7. WITJES VM, de Hullu JA, Hermkens DMA, Smolders YHCM, et al
   Nationwide implementation and evaluation of the Tumor-First workflow for genetic testing in ovarian carcinoma.
   Int J Cancer. 2025 Apr 16. doi: 10.1002/ijc.35440.
   

   >> Share

   
   March 2025
8. WEI W, Zhang Y, Li Y, Huang J, et al
   Hypoxia-mediated high expression of TRIM15 promotes malignant progression of high-grade serous ovarian cancer through activation of AKT signaling pathway by K63 ubiquitination.
   Int J Cancer. 2025 Mar 3. doi: 10.1002/ijc.35387.
   

   >> Share

   
   January 2025
9. LOFLING LL, Stoer NC, Sloan EK, Nafisi S, et al
   Beta-blockers and epithelial ovarian cancer survival: A Norwegian population-based cohort study.
   Int J Cancer. 2025 Jan 26. doi: 10.1002/ijc.35348.
   

   >> Share

   
   
10. LUND E, Busund LR, Holden L
    Curvilinear incidence models for parity in the entire fertility range for cancers of the breast, ovary, and endometrium: A follow-up of the Norwegian 1960 Census.
    Int J Cancer. 2025 Jan 3. doi: 10.1002/ijc.35312.
    

    >> Share

    
    December 2024
11. VERROU E, Koutoukoglou P, Kontana E, Gogolopoulos S, et al
    Incidence, characteristics and outcome of therapy-related myeloid neoplasms in women with epithelial ovarian cancer after exposure to poly-ADPribose polymerase inhibitors: A cancer center experience.
    Int J Cancer. 2024 Dec 17. doi: 10.1002/ijc.35299.
    

    >> Share

    
    
12. HUNG FH, Peng HP, Hung CF, Hsieh LL, et al
    Performance evaluation of predictive models for detecting MMR gene mutations associated with Lynch syndrome in cancer patients in a Chinese cohort in Taiwan.
    Int J Cancer. 2024;155:2201-2210.
    

    >> Share

    
    November 2024
13. JENSEN A, Guleria S, Albieri V, Nohr B, et al
    Fertility treatment and risk of ovarian cancer in a large nationwide cohort of infertile Danish women.
    Int J Cancer. 2024 Nov 14. doi: 10.1002/ijc.35251.
    

    >> Share

    
    October 2024
14. BIGNOTTI E, Simeon V, Ardighieri L, Kuhn E, et al
    TP53 mutations and survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: Results of the MITO16A/MaNGO OV-2 study.
    Int J Cancer. 2024 Oct 16. doi: 10.1002/ijc.35203.
    

    >> Share

    
    September 2024
15. JONSSON S, Jonsson H, Lundin E, Haggstrom C, et al
    Pelvic inflammatory disease and risk of borderline ovarian tumors: A national population-based case-control study in Sweden.
    Int J Cancer. 2024 Sep 25. doi: 10.1002/ijc.35180.
    

    >> Share

    
    
16. NA R, Jordan SJ, DeFazio A, Williams M, et al
    Use of menopausal hormone therapy before and after diagnosis and ovarian cancer survival-A prospective cohort study in Australia.
    Int J Cancer. 2024 Sep 2. doi: 10.1002/ijc.35154.
    

    >> Share

    
    August 2024
17. VLEDDER A, Paijens ST, Loiero D, Maagdenberg A, et al
    B cells critical for outcome in high grade serous ovarian carcinoma.
    Int J Cancer. 2024 Aug 22. doi: 10.1002/ijc.35149.
    

    >> Share

    
    July 2024
18. 
    Expression of Concern: miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6.
    Int J Cancer. 2024 Jul 31. doi: 10.1002/ijc.35121.
    

    >> Share

    
    
19. MORO F, Ciancia M, Zace D, Vagni M, et al
    Role of artificial intelligence applied to ultrasound in gynecology oncology: A systematic review.
    Int J Cancer. 2024 Jul 11. doi: 10.1002/ijc.35092.
    

    >> Share

    
    June 2024
20. 
    Correction to "Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer".
    Int J Cancer. 2024 Jun 21. doi: 10.1002/ijc.35059.
    

    >> Share

    
    
21. ALHARBI M, Lai A, Godbole N, Guanzon D, et al
    Enhancing precision targeting of ovarian cancer tumor cells in vivo through extracellular vesicle engineering.
    Int J Cancer. 2024 Jun 7. doi: 10.1002/ijc.35055.
    

    >> Share

    
    May 2024
22. CHAO X, Kai Z, Wu H, Wang J, et al
    Fragmentomics features of ovarian cancer.
    Int J Cancer. 2024 May 20. doi: 10.1002/ijc.34981.
    

    >> Share

    
    
23. HUANG C, Bu H, Wang Y, Chu R, et al
    Association between coffee and tea consumption and ovarian cancer incidence: A prospective analysis in the PLCO dataset.
    Int J Cancer. 2024 May 11. doi: 10.1002/ijc.34982.
    

    >> Share

    
    
24. TAGUCHI A, Kato K, Furusawa A, Hara K, et al
    Heterogeneous treatment effect of dose-dense paclitaxel plus carboplatin therapy for advanced ovarian cancer.
    Int J Cancer. 2024 May 7. doi: 10.1002/ijc.34996.
    

    >> Share

    
    
25. FROMHAGE G, Obermayr E, Bednarz-Knoll N, Van Gorp T, et al
    Loss of copy numbers of retrotransposons (HERVK) on chromosome 7p11.2 impacts EGFR (Epidermal Growth Factor Receptor)-induced phenotypes for platinum sensitivity and long-term survival in ovarian cancer-A study from the OVCAD consortium.
    Int J Cancer. 2024 May 6. doi: 10.1002/ijc.34976.
    

    >> Share

    
    April 2024
26. OBERMAYR E, Mohr T, Schuster E, Braicu EI, et al
    Gene expression markers in peripheral blood and outcome in patients with platinum-resistant ovarian cancer: A study of the European GANNET53 consortium.
    Int J Cancer. 2024 Apr 27. doi: 10.1002/ijc.34978.
    

    >> Share

    
    March 2024
27. DUUS AH, Hannibal CG, Baandrup L, Zheng G, et al
    Prediagnostic use of menopausal hormone therapy and long-term survival of localized epithelial ovarian cancer: The Extreme study.
    Int J Cancer. 2024 Mar 26. doi: 10.1002/ijc.34936.
    

    >> Share

    
    
28. HOLY P, Hlavac V, Seborova K, Susova S, et al
    Targeted DNA sequencing of high-grade serous ovarian carcinoma reveals association of TP53 mutations with platinum resistance when combined with gene expression.
    Int J Cancer. 2024 Mar 6. doi: 10.1002/ijc.34908.
    

    >> Share

    
    February 2024
29. GIZAW M, Parkin DM, Stoter O, Bukirwa P, et al
    Ovarian cancer survival in sub-Saharan Africa by human development index and histological subtypes: A population-based registry study.
    Int J Cancer. 2024 Feb 10. doi: 10.1002/ijc.34877.
    

    >> Share

    
    January 2024
30. WANG X, Sun J, Liu Y, Lin Z, et al
    Trps1 predicts poor prognosis in advanced high grade serous ovarian carcinoma.
    Int J Cancer. 2024 Jan 11. doi: 10.1002/ijc.34844.
    

    >> Share

    
    October 2023
31. XIA D, Xu X, Du P
    Comments on "Randomized, two-arm, non-comparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045".
    Int J Cancer. 2023 Oct 31. doi: 10.1002/ijc.34785.
    

    >> Share

    
    
32. KIM YN, Joung JG, Park E, Kim JW, et al
    Reply to: Comments on "Randomized, two-arm, non-comparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045".
    Int J Cancer. 2023 Oct 31. doi: 10.1002/ijc.34786.
    

    >> Share

    
    
33. HERZOG C, Jones A, Evans I, Reisel D, et al
    Plasma cell-free DNA methylation analysis for ovarian cancer detection: Analysis of samples from a case-control study and an ovarian cancer screening trial.
    Int J Cancer. 2023 Oct 20. doi: 10.1002/ijc.34757.
    

    >> Share

    
    August 2023
34. KIM YN, Joung JG, Park E, Kim JW, et al
    Randomized, two-arm, noncomparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045.
    Int J Cancer. 2023 Aug 21. doi: 10.1002/ijc.34696.
    

    >> Share

    
    June 2023
35. FRANDSEN CLB, Svendsen PF, Nohr B, Viuff JH, et al
    Risk of epithelial ovarian tumors among women with polycystic ovary syndrome: A nationwide population-based cohort study.
    Int J Cancer. 2023 Jun 26. doi: 10.1002/ijc.34574.
    

    >> Share

    
    May 2023
36. FORTNER RT, Trewin-Nybraten CB, Paulsen T, Langseth H, et al
    Characterization of ovarian cancer survival by histotype and stage: A nationwide study in Norway.
    Int J Cancer. 2023 May 25. doi: 10.1002/ijc.34576.
    

    >> Share

    
    March 2023
37. SENKUS E, Delaloge S, Domchek SM, Conte P, et al
    Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: subgroup analyses from the phase III OlympiAD trial.
    Int J Cancer. 2023 Mar 27. doi: 10.1002/ijc.34525.
    

    >> Share

    
    
38. SILVA R, Glennon K, Metoudi M, Moran B, et al
    Unveiling the epigenomic mechanisms of acquired platinum-resistance in high-grade serous ovarian cancer.
    Int J Cancer. 2023 Mar 8. doi: 10.1002/ijc.34496.
    

    >> Share

    
    February 2023
39. CHANG VC, Rhee J, Berndt SI, Moore SC, et al
    Serum perfluorooctane sulfonate and perfluorooctanoate and risk of postmenopausal breast cancer according to hormone receptor status: An analysis in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
    Int J Cancer. 2023 Feb 26. doi: 10.1002/ijc.34487.
    

    >> Share

    
    January 2023
40. HUANG RY, Huang KJ, Chen KC, Hsiao SM, et al
    Immune-Hot tumor features associated with recurrence in early-stage ovarian clear cell carcinoma.
    Int J Cancer. 2023 Jan 11. doi: 10.1002/ijc.34428.
    

    >> Share

    
    December 2022
41. VELLE A, Pesenti C, Grassi T, Beltrame L, et al
    A comprehensive investigation of histotype-specific microRNA and their variants in stage I epithelial ovarian cancers.
    Int J Cancer. 2022 Dec 21. doi: 10.1002/ijc.34408.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share